Huazhi Rougan Granule as an Add-On Therapy for H. Pylori Infection With Metabolic-associated Steatohepatitis

Exclusion Criteria

• •1. Individuals with fatty liver caused by chronic heart failure, malnutrition, or pregnancy; those with fatty liver syndrome in encephalopathy, abetalipoproteinemia, or localized fatty liver;
• •2. Patients with severe fatty liver accompanied by ascites, edema, hyponatremia, hypokalemia, or other signs suggestive of cirrhosis; those with hepatitis or cirrhosis caused by viruses, drug toxicity, autoimmune diseases, or other factors;
• •3. Individuals using hepatoprotective, enzyme-lowering, or lipid-lowering medications that may interfere with efficacy evaluation;
• •4. Pregnant or lactating women;
• •5. Patients with severe primary cardiovascular, renal, or other life-threatening diseases;
• •6. Individuals with a history of cancer;
• •7. Those positive for HCV antibody, HIV antibody, or HBsAg with detectable HBV-DNA levels;
• •8. Individuals with a history of alcohol abuse (≥210 g/week for males or ≥140 g/week for females) or substance abuse;
• •9. Those with known hypersensitivity to any component of the study drug;
• •10. Participation in another clinical trial within 3 months prior to screening;
• •11. Use of Chinese herbal medicines for the treatment of non-alcoholic simple fatty liver within 2 weeks prior to screening;
• •12. Individuals deemed unsuitable for participation by the investigator.